Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Endothelin Role In COronary Microcirculation (ERICOM)

19. juni 2026 opdateret af: Liverpool University Hospitals NHS Foundation Trust

Determining the Role of Endothelin in Microcirculatory Function in Myocardial Ischaemia

Coronary microvascular dysfunction is an important cause of angina in patients who do not have significant blockages in the major coronary arteries. Previous studies suggest that endothelin-1, a naturally occurring substance that causes blood vessel constriction, may contribute to abnormalities in the coronary microcirculation.

The ERICOM study aims to investigate whether treatment with bosentan, an endothelin receptor antagonist, can improve coronary microvascular function in patients with angina and evidence of coronary microvascular dysfunction. Participants undergo cardiovascular magnetic resonance (CMR) imaging before and after treatment, and some participants also undergo invasive coronary physiological assessment.

The results of this study may improve understanding of the role of endothelin-1 in coronary microvascular dysfunction and help identify new treatment strategies for patients with angina and non-obstructive coronary artery disease.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Coronary microvascular dysfunction (CMD) is increasingly recognised as a major cause of myocardial ischaemia and angina in patients without obstructive epicardial coronary artery disease. CMD is a key mechanism underlying ischaemia with non-obstructive coronary arteries (INOCA) and is associated with impaired quality of life, recurrent healthcare utilisation, and adverse cardiovascular outcomes.

Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor peptide that has been implicated in endothelial dysfunction, vascular inflammation, and microvascular dysregulation. Elevated circulating ET-1 concentrations have been reported in patients with microvascular angina and may contribute to increased coronary microvascular resistance and impaired myocardial perfusion.

The ERICOM study is a prospective, single-arm mechanistic study designed to investigate the relationship between ET-1 and coronary microvascular dysfunction and to assess the effects of endothelin receptor antagonism on coronary microvascular function.

Participants with angina symptoms and evidence of coronary microvascular dysfunction undergo baseline clinical assessment, blood sampling for ET-1 measurement, and stress cardiovascular magnetic resonance (CMR) imaging. Participants receive bosentan therapy for four weeks followed by repeat stress CMR imaging. A subset of participants undergoes invasive coronary angiography with physiological assessment, including measurements of coronary flow reserve (CFR), index of microcirculatory resistance (IMR), fractional flow reserve (FFR), and resting full-cycle ratio (RFR).

The primary objective is to determine whether bosentan therapy improves coronary microvascular function as assessed by serial CMR-derived myocardial perfusion measurements. Secondary objectives include evaluating associations between ET-1 concentrations and CMD, assessing relationships between invasive and non-invasive measures of coronary microvascular function, and exploring mechanistic pathways linking endothelin signalling and coronary microvascular disease.

The study is sponsored by Liverpool University Hospitals NHS Foundation Trust and conducted in accordance with Good Clinical Practice, Research Ethics Committee approval, and Health Research Authority approval.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

45

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Clinical diagnosis of symptomatic angina, defined as the presence of substernal chest pain or discomfort provoked by exertion or emotional stress and relieved by rest and/or glyceryl trinitrate (nitroglycerin).
  2. Age 18 years or older.
  3. Able and willing to provide written informed consent.
  4. Able and willing to adhere to study procedures and follow-up requirements.

Exclusion Criteria:

  1. Symptoms consistent with unstable angina, including:
  2. Angina at rest lasting more than 20 minutes.
  3. New-onset severe angina.
  4. Angina increasing in frequency, duration, or occurring at a lower threshold.
  5. Angina occurring following a recent myocardial infarction.
  6. Known significant coronary artery disease, defined as previous investigations demonstrating greater than 50% epicardial coronary artery stenosis.
  7. Uncontrolled hypertension, defined as clinic blood pressure greater than 140/90 mmHg despite treatment with three or more antihypertensive medications.
  8. Pregnancy or breastfeeding.
  9. Poorly controlled asthma as defined in the study protocol.
  10. Severe heart failure or symptoms of active heart failure.
  11. Significant chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m².
  12. Clinical evidence of active infection at the time of recruitment.
  13. Significant liver disease, defined as Child-Pugh Class B or C liver disease (or worse than Child-Pugh Class A).
  14. Systolic blood pressure less than 90 mmHg at the time of recruitment.
  15. Previously documented allergy or hypersensitivity to endothelin receptor antagonists.
  16. Concurrent use of medications contraindicated with endothelin receptor antagonist therapy.
  17. Requirement for invasive coronary angiography for another clinical indication, including but not limited to valvular heart disease assessment or intervention.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Interventional group
45 participants will undergo Cardiac MRI and invasive catheterization, and then given PO Endothelin Receptors Antagonists for 4 weeks. Participants will then have a repeat cardiac MRI.
Diagnostisk test: Cardiac MRI
Cardiac stress/perfusion MRI scan
Procedure: Invasive Coronary Angiogram
Invasive Coronary Angiogram with pressure wire assessments
Medicin: Endothelin Receptor Antagonist
Participants will be given PO Bosentan 125 mg BD for 4 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Myocardial Perfusion Reserve Index (MPRI) following Bosentan treatment
Tidsramme: Baseline and 4 weeks
Within-participant change in myocardial perfusion reserve index (MPRI) measured by stress cardiovascular magnetic resonance imaging before and after four weeks of Bosentan therapy.
Baseline and 4 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Liverpool University Hospitals NHS Foundation Trust

Efterforskere

  • Ledende efterforsker: Michael Fisher, NHS University Hospitals of Liverpool Group

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juli 2023

Primær færdiggørelse (Faktiske)

31. juli 2025

Studieafslutning (Anslået)

1. august 2026

Datoer for studieregistrering

Først indsendt

19. juni 2026

Først indsendt, der opfyldte QC-kriterier

19. juni 2026

Først opslået (Faktiske)

26. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • SP0323

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Mikrovaskulær angina

Kliniske forsøg med Cardiac MRI

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Türkiye

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner